Cancer-related stroke accounts for 5-10% of embolic strokes of undetermined source and is primarily driven by hypercoagulability, highlighting the need for personalized antithrombotic therapies.
This review highlights the growing incidence of cancer-related stroke, which accounts for 5-10% of ESUS, and emphasizes the need for personalized therapy strategies given the lack of consensus on treatment.
BACKGROUND: Cancer and ischemic stroke are two common diseases that threaten human health and have become the main causes of death in the world. It is estimated that one-in-ten patients with ischemic stroke have concomitant cancer, and this incidence is expected to increase as improvements in medical technology extends the life expectancy of cancer patients. DISCUSSION: Cancer-related stroke (CRS) refers to unexplained ischemic stroke in patients with active cancer that cannot be explained by current stroke mechanisms. Available evidence suggests that CRS accounts for 5-10% of embolic stroke of undetermined source (ESUS). Although the incidence of CRS is gradually increasing, its underlying pathogenesis remains unclear. Also, there is no consensus on acute treatment and secondary prevention of stroke. CONCLUSION: In this review, we retrospectively analyzed the incidence, mechanisms of CRS, its potential as a new stroke subtype, options for acute treatment, secondary prevention strategies, and disease progression, with the aim of attempting to explore personalized therapy strategies.
Chen et al. (Mon,) conducted a review in Cancer-related stroke. Cancer-related stroke accounts for 5-10% of embolic strokes of undetermined source and is primarily driven by hypercoagulability, highlighting the need for personalized antithrombotic therapies.